Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Monte Rosa Therapeutics Inc’s stock clocked out at $7.17, up 0.84% from its previous closing price of $7.11. In other words, the price has increased by $0.84 from its previous closing price. On the day, 0.6 million shares were traded. GLUE stock price reached its highest trading level at $7.46 during the session, while it also had its lowest trading level at $7.09.
Ratios:
To gain a deeper understanding of GLUE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.03 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 28 ’24 when Versant Venture Capital VI, L. sold 89,990 shares for $9.66 per share. The transaction valued at 869,240 led to the insider holds 2,007,948 shares of the business.
Versant Venture Capital VI, L. sold 67,905 shares of GLUE for $621,801 on Oct 29 ’24. The 10% Owner now owns 1,573,453 shares after completing the transaction at $9.16 per share. On Oct 28 ’24, another insider, Wallace Owen B., who serves as the Officer of the company, bought 20,000 shares for $12.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 440501152 and an Enterprise Value of 242008944. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.67 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 16.161 whereas that against EBITDA is -1.999.
Stock Price History:
Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -12.92%, while the 200-Day Moving Average is calculated to be 20.44%.
Shares Statistics:
It appears that GLUE traded 2.75M shares on average per day over the past three months and 1032930 shares per day over the past ten days. A total of 61.38M shares are outstanding, with a floating share count of 46.20M. Insiders hold about 24.81% of the company’s shares, while institutions hold 68.59% stake in the company. Shares short for GLUE as of 1734048000 were 8404331 with a Short Ratio of 3.06, compared to 1731628800 on 11152201. Therefore, it implies a Short% of Shares Outstanding of 8404331 and a Short% of Float of 24.990000000000002.
